Syndax Pharmaceuticals Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Syndax Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syndax Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Syndax Pharmaceuticals.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, November, 2nd. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.04. The firm had revenue of $0.38 million for the quarter. Syndax Pharmaceuticals had a negative net margin of 4,656.63% and a negative trailing twelve-month return on equity of 77.47%.
View Syndax Pharmaceuticals' earnings history.

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SNDX shares have increased by 104.8% and is now trading at $24.15.
View which stocks have been most impacted by COVID-19.

12 brokers have issued twelve-month price objectives for Syndax Pharmaceuticals' shares. Their forecasts range from $15.00 to $33.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $27.50 in the next year. This suggests a possible upside of 13.9% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Syndax Pharmaceuticals include Insmed (INSM), Arvinas (ARVN), Hypera (HYPMY), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), Karuna Therapeutics (KRTX), MorphoSys (MOR), Agios Pharmaceuticals (AGIO), ALX Oncology (ALXO), Pacira BioSciences (PCRX), OPKO Health (OPK), Rocket Pharmaceuticals (RCKT), Amicus Therapeutics (FOLD), Alkermes (ALKS) and Corcept Therapeutics (CORT).
View all of SNDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (8.09%), BlackRock Inc. (5.68%), Frazier Management LLC (3.44%), Ghost Tree Capital LLC (3.30%), Orbimed Advisors LLC (2.87%) and Dimensional Fund Advisors LP (1.90%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael A Metzger, Michael L Meyers and Peter Ordentlich.
View institutional ownership trends for Syndax Pharmaceuticals.

SNDX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Dimensional Fund Advisors LP, Nuveen Asset Management LLC, Russell Investments Group Ltd., GSA Capital Partners LLP, Trexquant Investment LP, Virtus ETF Advisers LLC, and State of Wisconsin Investment Board. Company insiders that have sold Syndax Pharmaceuticals company stock in the last year include Michael A Metzger, and Peter Ordentlich.
View insider buying and selling activity for Syndax Pharmaceuticals or view top insider-selling stocks.

SNDX stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Ghost Tree Capital LLC, Avoro Capital Advisors LLC, BlackRock Inc., Acuta Capital Partners LLC, Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, and Tri Locum Partners LP. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, and Michael L Meyers.
View insider buying and selling activity for Syndax Pharmaceuticals or or view top insider-buying stocks.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNDX stock can currently be purchased for approximately $24.15.

Syndax Pharmaceuticals has a market capitalization of $986.99 million and generates $1.52 million in revenue each year. The company earns $-56,050,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

Syndax Pharmaceuticals employs 35 workers across the globe.

The official website for Syndax Pharmaceuticals is www.syndax.com.

Syndax Pharmaceuticals is headquartered at 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]